| This article has been cited by |
| 1 | First experiences with a tool to measure the level of clinical information present in adverse drug reaction reports | |
| Ingrid Oosterhuis,Leàn Rolfes,Corine Ekhart,Annemarie Muller-Hansma,Linda Härmark |
| Expert Opinion on Drug Safety.2018;17(2)111 |
| [DOI] |
|
| 2 | System of adverse drug reactions reporting: What, where, how, and whom to report? | |
| Vivekanandan Kalaiselvan,Pranay Kumar,Prabhakar Mishra,Gyanendra Singh |
| Indian Journal of Critical Care Medicine.2015;19(9)564 |
| [DOI] |
|
| 3 | Audit to evaluate the completeness of adverse drug reporting in an ADR monitoring centre in Tamilnadu | |
| Shanmugapriya S.,Bhuvaneswari K.,Karthika P. |
| Indian Journal of Medical Specialities.2017;8(4)175 |
| [DOI] |
|
| 4 | Public-private partnership (3Ps) in ensuring safe use of medicines: An Indian experience | |
| Vivekanandan Kalaiselvan,Shatrunajay Shukla,Shubhang Arora,Tarani Prakash Shrivastava,Rajeev Singh Raghuvanshi |
| Frontiers in Public Health.2022;10(4)175 |
| [DOI] |
|
| 5 | An overview of the pharmacovigilance system in India | |
| Niti Mittal,Rakesh Mittal,M. C. Gupta |
| Clinical Research and Regulatory Affairs.2016;33(1)4 |
| [DOI] |
|
| 6 | Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase® from 1997 to 2017 | |
| Josiah Tatenda Masuka,Star Khoza |
| BMC Public Health.2019;19(1)4 |
| [DOI] |
|
| 7 | Best Practices for Improving the Quality of Individual Case Safety Reports in Pharmacovigilance | |
| Rishi Kumar,Pranay Kumar,Vivekanandan Kalaiselvan,Ismeet Kaur,G. N. Singh |
| Therapeutic Innovation & Regulatory Science.2016;50(4)464 |
| [DOI] |
|
| 8 | Revue de la littérature sur la pharmacovigilance des médicaments issus des pharmacopées traditionnelles. Partie II : évaluation et prévention des risques | |
| K. Ouoba,H. Lehmann,J.-Y. Pabst,R. Semde |
| Annales Pharmaceutiques Françaises.2022;80(5)635 |
| [DOI] |
|
| 9 | Risk of Intussusception with Rotavirus Vaccine | |
| Vivekanandan Kalaiselvan,Prasad Thota,Vipin Kumar,Madhvi Singh Rathore,Anusha Thota,Gyanendra Nath Singh |
| The Indian Journal of Pediatrics.2017;84(2)97 |
| [DOI] |
|
| 10 | Risk of Intussusception with Rotavirus Vaccine | |
| Rishi Kumar,V. Kalaiselvan,G. N. Singh |
| The Indian Journal of Pediatrics.2018;84(2)291 |
| [DOI] |
|
| 11 | An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme | |
| Josiah Tatenda Masuka,Star Khoza |
| Pharmacology Research & Perspectives.2020;8(5)291 |
| [DOI] |
|
